Last checked at 3 Apr 2009 09:22
Deltex Medical Group plc
Directors' share dealings
3 April 2009 - Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that New England Partners Capital ("NEPC"), has today notified the Company that on 2 April 2009 it disposed of its remaining interest in the Company of 594,211 ordinary shares of 1p each at 8 pence per share. Edwin Snape, a non-executive Director, is a principal of New England Partners Capital, a venture capital fund which is in the process of being wound up.
As a result, Edwin Snape, through his role as a principal of Nexus Medical Partners, a Deltex Medical shareholder, and through his personal holdings now has an interest in 3,884,685 ordinary shares of 1p each, representing 3.87 per cent. of the Company's issued share capital.
Edwin Snape, said:
"Nexus continues to be a shareholder in the Company and has been very supportive of the Company's initiative to expand its operations in the US."
For further information, please contact:-
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman njk@deltexmedical.com
Andy Hill, Chief Executive ahill@deltexmedical.com
Ewan Phillips, Finance Director eap@deltexmedical.com
Nominated Adviser & Broker
Arden Partners plc 020 7398 1630
Chris Hardie chris.hardie@arden-partners.com
Matthew Armitt matthew.armitt@arden-partners.com
Notes for Editors
Deltex Medical manufactures and markets the CardioQ-ODM(TM) monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.
The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.
There are already over 1,600 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. Over 1,000 patients a week are treated using the CardioQ-ODM. In addition, there are currently approximately 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-
Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works
Proved that the CardioQ-ODM works in a wide range of surgical procedures
Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.
The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.